Schonfeld Strategic Advisors LLC Has $3.54 Million Position in CVRx, Inc. (NASDAQ:CVRX)

Schonfeld Strategic Advisors LLC lessened its stake in CVRx, Inc. (NASDAQ:CVRX - Free Report) by 48.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 279,310 shares of the company's stock after selling 265,990 shares during the quarter. Schonfeld Strategic Advisors LLC owned 1.15% of CVRx worth $3,539,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Emerald Mutual Fund Advisers Trust increased its stake in shares of CVRx by 28.8% in the fourth quarter. Emerald Mutual Fund Advisers Trust now owns 370,813 shares of the company's stock worth $4,698,000 after acquiring an additional 82,978 shares during the last quarter. Northern Trust Corp increased its position in CVRx by 4.3% in the 4th quarter. Northern Trust Corp now owns 138,883 shares of the company's stock worth $1,760,000 after purchasing an additional 5,671 shares during the last quarter. Tudor Investment Corp ET AL raised its stake in shares of CVRx by 19.5% during the 4th quarter. Tudor Investment Corp ET AL now owns 75,885 shares of the company's stock worth $961,000 after purchasing an additional 12,403 shares in the last quarter. Quarry LP acquired a new stake in shares of CVRx during the 4th quarter valued at about $69,000. Finally, Boothbay Fund Management LLC acquired a new stake in shares of CVRx during the 4th quarter valued at about $127,000. Hedge funds and other institutional investors own 75.27% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on CVRX shares. Canaccord Genuity Group cut their price objective on shares of CVRx from $23.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, April 8th. Piper Sandler lifted their price objective on shares of CVRx from $16.00 to $20.00 and gave the company an "overweight" rating in a research note on Wednesday, February 5th. Lake Street Capital lowered their target price on shares of CVRx from $19.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, April 8th. William Blair upgraded CVRx from a "market perform" rating to an "outperform" rating in a report on Tuesday, January 14th. Finally, Craig Hallum increased their price objective on CVRx from $20.00 to $22.00 and gave the company a "buy" rating in a report on Friday, January 17th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, CVRx currently has an average rating of "Buy" and a consensus target price of $17.60.

CVRx Stock Performance

CVRX stock traded up $0.04 during mid-day trading on Wednesday, reaching $7.47. 235,557 shares of the stock traded hands, compared to its average volume of 314,466. The company has a quick ratio of 10.23, a current ratio of 12.06 and a debt-to-equity ratio of 0.69. The business has a 50-day moving average of $9.64 and a two-hundred day moving average of $12.68. The firm has a market capitalization of $194.67 million, a PE ratio of -2.78 and a beta of 1.39. CVRx, Inc. has a 52 week low of $5.81 and a 52 week high of $18.55.

CVRx (NASDAQ:CVRX - Get Free Report) last released its earnings results on Tuesday, February 4th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%. As a group, equities analysts predict that CVRx, Inc. will post -1.91 EPS for the current fiscal year.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.